1. Home
  2. VTEX vs DRUG Comparison

VTEX vs DRUG Comparison

Compare VTEX & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VTEX

VTEX

VTEX

HOLD

Current Price

$3.61

Market Cap

755.3M

Sector

Technology

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$68.02

Market Cap

778.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTEX
DRUG
Founded
1999
2019
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Pharmaceuticals and Biotechnology
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
755.3M
778.4M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
VTEX
DRUG
Price
$3.61
$68.02
Analyst Decision
Buy
Strong Buy
Analyst Count
6
6
Target Price
$5.97
$129.25
AVG Volume (30 Days)
738.5K
116.8K
Earning Date
05-07-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.78
N/A
Revenue Next Year
$9.63
N/A
P/E Ratio
$43.33
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.84
$39.70
52 Week High
$4.73
$123.75

Technical Indicators

Market Signals
Indicator
VTEX
DRUG
Relative Strength Index (RSI) 42.11 35.52
Support Level $3.64 $64.82
Resistance Level $3.79 $77.16
Average True Range (ATR) 0.13 3.63
MACD 0.00 -1.39
Stochastic Oscillator 64.06 0.21

Price Performance

Historical Comparison
VTEX
DRUG

About VTEX VTEX

Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. The VTEX platform is designed to be composable and complete, enabling its customers to seamlessly implement, optimize, test, and expand both B2C and B2B digital experiences. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: